A Phase 3 lung cancer trial results in a more than threefold increase in BeyondSpring’s stock price

During premarket trading Wednesday, shares of BeyondSpring Inc. BYSI, +1.58% more than tripled — up 242 percent — after the biopharmaceutical company announced that a Phase 3 trial of its lung cancer treatment had met its primary and secondary endpoints. After closing at a record low last week, the stock was set to open at … Continue reading A Phase 3 lung cancer trial results in a more than threefold increase in BeyondSpring’s stock price